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We thank Dr Sheinberg and colleagues’1 for raising the issue of
hepatobiliary disorders mentioned in the European Public
Assessment Report (EPAR) but not included in the 24-week
report.2 This was due to the following reasons. First, the general
safety reporting scheme was based on common adverse events
(≥2% among reported adverse events, seen in table 2 of the paper),
and overall major safety indices such as comparison of total
treatment-emergent adverse events and serious adverse events. The
groups of adverse events were those that were usually expected (or
considered to be expected) to occur with etanercept (ETN) use,
such as serious infections, malignancies or injection site reactions.
All of these were discussed in the 24-week paper. The imbalance of
system organ class (SOC) hepatobiliary disorders found in the SB4
treatment group did not ﬁt into any of these categories, as each dis-
tinct hepatobiliary event (such as bile duct stone, etc.) did not
occur frequently enough to be ≥2%, and also did not ﬁt into the
categories of serious infections, malignancies or injection site reac-
tions. Second, the distribution of the adverse events from SOC
hepatobiliary disorders was not clinically homogenous and was
considered a mixture of two distinct areas of drug safety: either the
potential for increased drug-related hepatocellular toxicity, or
the propensity for increased risk for bile stones; so that reporting
the 11 patients as a whole would have been misleading. When con-
sidering each area, among the 11 patients identiﬁed, only 3 patients
purely belonged to the hepatocellular category. This was not con-
sidered to be a substantial difference, and as also seen in table 2,
from the 24-week report, the incidence of alanine transaminase
and asparate transaminase increases reported as an adverse event
was comparable between the SB4 and reference ETN treatment
groups (5.0% vs 4.7% and 2.3% vs 2.7%, respectively). Of the
remaining eight patients who had biliary events, two were found
incidentally to have asymptomatic gallstones, after sonographic
evaluation ordered for elevated liver enzymes. Therefore, the
numerical imbalance is smaller than initially thought. Third, these
patients usually had a biliary risk factor at baseline, such as older
age, obesity, prior history of gallstones, medications or comorbidi-
ties, including cardiovascular risk/disease.3–5 When systematically
analysed at the whole population level by baseline medical history
and concomitant medications, there was a modest but generally
higher trend of these biliary risk factors in the SB4 treatment group
compared with the ETN treatment group (table 1), and this trend
was considered to explain the substantial proportion of biliary risk
of the SB4 population. Therefore, it was considered that the higher
occurrence of biliary events was likely to be due to chance rather
than to true SB4 causality, this was commented on in the EPAR.
As the 11 patients were heterogeneous in terms of safety classiﬁ-
cation, and the strength of causalityQ2 for increased biliary risk by
SB4 was questionable, it was felt inappropriate for us to discuss
the imbalance of the SOC hepatobiliary disorders in the 24-week
paper. It is to be noted that no additional hepatic or biliary risk
was found beyond what was described in the EPAR, up to the end
of the 100-week extension study. It is our opinion that extra sur-
veillance for gallstones when treating patients with SB4 does not
seem to be necessary, although the sponsor will monitor for this.
We hope that this will reassure Dr Scheinberg and colleagues
for the safety of SB4, as well as to help maintain his enthusiasm
on biosimilars.
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Table 1 Summary of baseline imbalances of biliary risk factors in
the total study population
Biliary risk factor Summary results*
Age Age ≥40 years is 2.1% more prevalent in SB4 over ETN
Sex Female sex is 2.3% more prevalent in ETN over SB4
BMI SB4 has more obese patients† than ETN (27.8% vs 21.5%)
Hypertension SB4 12.6% higher prevalence over ETN
Diabetes SB4 16.9% higher prevalence over ETN
Dyslipidaemia SB4 24.2% higher prevalence over ETN
Coronary artery
disease
SB4 35.9% higher prevalence over ETN
Hypothyroidism ETN 22.2% higher prevalence over SB4
Prior bile stone
history
ETN 11.7% higher prevalence over SB4
Corticosteroid use ETN and SB4 are almost similar (165 vs 168 patients)
Thiazide use SB4 58.9% higher use over ETN
*“over” means risk ratio of patients (eg, SB4: ETN patient incidence ratio or vice versa).
†Defined as BMI ≥30 kg/m2.
BMI, body mass index; ETN, etanercept.
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